HC Wainwright Reiterates “Buy” Rating for Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $45.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 121.57% from the stock’s current price.

Several other analysts have also issued reports on ORKA. Lifesci Capital initiated coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price target on the stock. Jefferies Financial Group initiated coverage on Oruka Therapeutics in a research note on Friday, September 13th. They set a “buy” rating and a $40.00 price target on the stock. Stifel Nicolaus initiated coverage on Oruka Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $49.00 price objective for the company. Leerink Partnrs upgraded Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, Leerink Partners assumed coverage on Oruka Therapeutics in a research report on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 target price for the company. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Oruka Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $43.17.

Oruka Therapeutics Stock Down 2.2 %

ORKA opened at $20.31 on Friday. Oruka Therapeutics has a 1-year low of $18.20 and a 1-year high of $53.88. The company has a 50 day simple moving average of $24.55. The company has a market capitalization of $710.83 million, a PE ratio of -3.24 and a beta of 0.78.

Institutional Trading of Oruka Therapeutics

Institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC acquired a new position in Oruka Therapeutics during the third quarter worth $343,000. The Manufacturers Life Insurance Company bought a new stake in shares of Oruka Therapeutics in the 3rd quarter worth about $1,037,000. Wellington Management Group LLP acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth about $2,013,000. Janus Henderson Group PLC bought a new position in Oruka Therapeutics during the 3rd quarter valued at about $5,840,000. Finally, Redmile Group LLC acquired a new position in Oruka Therapeutics in the third quarter valued at about $10,091,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.